Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tenax Therapeutics (TENX) Operating Expenses (2016 - 2026)

Tenax Therapeutics' Operating Expenses history spans 7 years, with the latest figure at $17.0 million for Q4 2017.

  • On a quarterly basis, Operating Expenses fell 74.78% to $17.0 million in Q4 2017 year-over-year; TTM through Dec 2017 was $9.2 million, a 85.63% decrease, with the full-year FY2025 number at $56.4 million, up 189.24% from a year prior.
  • Operating Expenses hit $17.0 million in Q4 2017 for Tenax Therapeutics, up from -$1.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for TENX hit a ceiling of $67.5 million in Q4 2016 and a floor of -$4.7 million in Q2 2016.
  • Historically, Operating Expenses has averaged $7.3 million across 4 years, with a median of $1.8 million in 2013.
  • The widest YoY moves for Operating Expenses: up 547.72% in 2016, down 245.01% in 2016.
  • Tracing TENX's Operating Expenses over 4 years: stood at $1.4 million in 2013, then surged by 633.77% to $10.4 million in 2015, then surged by 547.72% to $67.5 million in 2016, then tumbled by 74.78% to $17.0 million in 2017.
  • Business Quant data shows Operating Expenses for TENX at $17.0 million in Q4 2017, -$1.3 million in Q3 2017, and -$3.0 million in Q2 2017.